The law firm Schalla national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Instil Bio, Inc. (“Instil Bio” or “the Company”). UNTIL for violations of securities laws.
The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose information relevant to investors. Instil Bio announced on October 31, 2022 that it had notified the FDA that it had voluntarily suspended enrollment in a clinical trial due to manufacturing issues with one of its therapies. Manufacturing issues meant that patients in a clinical trial of ITIL-168 for advanced melanoma could not be properly dosed. Based on this news, shares of Instil Bio fell more than 33% in intraday trading.
If you are a shareholder who has suffered a loss, Click here to participate.
We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067 at 310-301-3335 to discuss your rights free of charge. You can also contact us via the law firm’s website at www.schallfirm.comor by email at bschall@schallfirm.com.
In this case, the class has not yet been certified and you will not be represented by a lawyer until it is certified. If you don’t do anything, you can remain absent.
The law firm of Schall represents investors around the world and specializes in securities class actions and shareholder disputes.
This press release may be considered an attorney’s solicitation in some jurisdictions under applicable laws and ethics rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005970/en/
